We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Comcast, Danaher, Amgen, Boeing and Canadian Pacific Railway
Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 24, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Comcast Corp. (CMCSA - Free Report) , Danaher Corp. (DHR - Free Report) , Amgen Inc. (AMGN - Free Report) , The Boeing Company (BA - Free Report) and Canadian Pacific Railway Limited (CP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Comcast, Danaher & Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Comcast Corp., Danaher Corp. and Amgen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Comcast shares have declined -6.1% in the year-to-date period against the Zacks Cable Television industry's decline of -7.3%. The Zacks analyst believes that Comcast persistently suffers from video-subscriber attrition due to cord cutting. Moreover, a leveraged balance sheet is a major concern.
However, Comcast is also benefiting from strength in broadband subscriber base and strong momentum in the wireless business. Its strategy to provide high-speed Internet at an affordable price plays a pivotal role in providing connectivity, improving customer wins and experience.
Media consumption and the work-from-home and online-learning waves bode well for Comcast's Internet business due to the recent pandemic. The company's streaming service Peacock gained significant traction within a short span and is a key catalyst in driving broadband sales.
Shares of Danaher have outperformed the Zacks Diversified Operations industry over the past year (+33.9% vs. -3.4%). The Zacks analyst believes that the company is poised to gain from Danaher Business System ("DBS"), healthy rewards to shareholders, buyout benefits, and product innovation in the quarters ahead. In fourth-quarter 2021, its earnings and sales surpassed estimates by 7.6% and 4.38%, respectively.
The company anticipates year-over-year core revenue growth of 10% for the first quarter of 2022 and mid-single digits for 2022.The impact of COVID-related testing is predicted to boost sales in the low-single digits in the first quarter. However, cost inflation and woes related to supply-chain restrictions might be worrying in the quarters ahead. High debts might inflate financial obligations and forex woes might be concerning.
Shares of Amgen have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+5.1% vs. -12.3%). The Zacks analyst believes that Amgen is rapidly advancing its robust pipeline of early and late-stage assets. Several phase III readouts are due in 2022. Lumakras, a first-in-class lung cancer treatment, is off to an excellent start while its label expansion studies are progressing rapidly. Amgen also boasts a strong biosimilars portfolio, which is an important long-term growth driver.
While key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales, increasing competition for its legacy products is hurting the same. However, pricing and competitive pressure are impacting many of Amgen's products and franchises. Several of Amgen's marketed drugs are facing increased pricing headwinds and continued COVID-19 headwinds.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Comcast, Danaher, Amgen, Boeing and Canadian Pacific Railway
For Immediate Release
Chicago, IL – March 24, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Comcast Corp. (CMCSA - Free Report) , Danaher Corp. (DHR - Free Report) , Amgen Inc. (AMGN - Free Report) , The Boeing Company (BA - Free Report) and Canadian Pacific Railway Limited (CP - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Stock Reports for Comcast, Danaher & Amgen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Comcast Corp., Danaher Corp. and Amgen Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Comcast shares have declined -6.1% in the year-to-date period against the Zacks Cable Television industry's decline of -7.3%. The Zacks analyst believes that Comcast persistently suffers from video-subscriber attrition due to cord cutting. Moreover, a leveraged balance sheet is a major concern.
However, Comcast is also benefiting from strength in broadband subscriber base and strong momentum in the wireless business. Its strategy to provide high-speed Internet at an affordable price plays a pivotal role in providing connectivity, improving customer wins and experience.
Media consumption and the work-from-home and online-learning waves bode well for Comcast's Internet business due to the recent pandemic. The company's streaming service Peacock gained significant traction within a short span and is a key catalyst in driving broadband sales.
(You can read the full research report on Comcast here >>>)
Shares of Danaher have outperformed the Zacks Diversified Operations industry over the past year (+33.9% vs. -3.4%). The Zacks analyst believes that the company is poised to gain from Danaher Business System ("DBS"), healthy rewards to shareholders, buyout benefits, and product innovation in the quarters ahead. In fourth-quarter 2021, its earnings and sales surpassed estimates by 7.6% and 4.38%, respectively.
The company anticipates year-over-year core revenue growth of 10% for the first quarter of 2022 and mid-single digits for 2022.The impact of COVID-related testing is predicted to boost sales in the low-single digits in the first quarter. However, cost inflation and woes related to supply-chain restrictions might be worrying in the quarters ahead. High debts might inflate financial obligations and forex woes might be concerning.
(You can read the full research report on Danaher here >>>)
Shares of Amgen have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+5.1% vs. -12.3%). The Zacks analyst believes that Amgen is rapidly advancing its robust pipeline of early and late-stage assets. Several phase III readouts are due in 2022. Lumakras, a first-in-class lung cancer treatment, is off to an excellent start while its label expansion studies are progressing rapidly. Amgen also boasts a strong biosimilars portfolio, which is an important long-term growth driver.
While key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales, increasing competition for its legacy products is hurting the same. However, pricing and competitive pressure are impacting many of Amgen's products and franchises. Several of Amgen's marketed drugs are facing increased pricing headwinds and continued COVID-19 headwinds.
(You can read the full research report on Amgen here >>>)
Other noteworthy reports we are featuring today include The Boeing Company and Canadian Pacific Railway Limited.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.